<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-73680</identifier>
<setSpec>0004-2927</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Drug delivery systems based on poly(e-caprolactone) for cancer treatment</dc:title>
<dc:description xml:lang="en">Chemotherapy agents have little or no specificity over cancer cells, resulting in lowtherapeutic concentrations at the tumor site (a consequence of a broad systemic distribution),and severe side effects. With the aim of avoiding cancer therapy failure, several approachessuch as design of new anticancer drugs, chemical engineering of conventional drugs anddevelopment of drug delivery systems have been proposed. The objective is to enhance druglocalization at the tumor region (by controlling its biodistribution profile) and, therefore, toincrease the anti-tumor efficacy (even in multi-drug resistant tumors), while reducingsystemic side effects. One of the most promising approaches to the problem is thedevelopment of drug nanocarriers based on the polymer poly(e-caprolactone). In this reviewwe will focus our attention on these polymeric colloids, particularly on the most significantcharacteristics and formulation procedures, and on their use as nanoplatforms for the deliveryof chemotherapy agents to the tumor site. Furthermore, the most recent in vitro and in vivoinvestigations on the subject are extensively reviewed(AU</dc:description>
<dc:creator>Ruiz, M. A</dc:creator>
<dc:creator>Sáez-Fernández, E</dc:creator>
<dc:creator>Arias, J. L</dc:creator>
<dc:language>en</dc:language>
<dc:source>Ars pharm;50(2): 83-96, abr.-jun. 2009. ilus, graf</dc:source>
<dc:identifier>ibc-73680</dc:identifier>
<dc:title xml:lang="es">Sistemas transportadores de fármacos basados en el polímero poly(e-caprolactona) para el tratamiento del cáncer</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d11545^s22078</dc:subject>
<dc:subject>^d9562^s22057</dc:subject>
<dc:subject>^d4401</dc:subject>
<dc:subject>^d2242^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d974^s29165</dc:subject>
<dc:type>article</dc:type>
<dc:date>200906</dc:date>
</metadata>
</record>
</ibecs-document>
